Kiniksa (KNSA) | Financial Analysis & Statements
Kiniksa Pharmaceuticals, Ltd. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
202.1M
Gross Profit
111.2M
54.99%
Operating Income
19.8M
9.78%
Net Income
14.2M
7.02%
EPS (Diluted)
$0.17
Balance Sheet Metrics
Total Assets
763.6M
Total Liabilities
196.0M
Shareholders Equity
567.6M
Debt to Equity
0.35
Cash Flow Metrics
Operating Cash Flow
47.6M
Free Cash Flow
53.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Kiniksa Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 677.6M | 423.2M | 270.3M | 220.2M | 38.5M |
| Cost of Goods Sold | 307.2M | 60.9M | 33.4M | 22.9M | 9.1M |
| Gross Profit | 370.3M | 362.3M | 236.9M | 197.3M | 29.4M |
| Gross Margin % | 54.7% | 85.6% | 87.6% | 89.6% | 76.4% |
| Operating Expenses | |||||
| Research & Development | 96.9M | 111.6M | 76.1M | 65.5M | 99.3M |
| Selling, General & Administrative | 196.3M | 168.0M | 129.4M | 98.0M | 85.9M |
| Other Operating Expenses | - | 128.3M | 56.5M | 24.1M | 835.0K |
| Total Operating Expenses | 293.1M | 407.9M | 262.0M | 187.5M | 186.1M |
| Operating Income | 77.2M | -45.6M | -25.2M | 9.8M | -156.6M |
| Operating Margin % | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | 1.3M | 97.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 11.6M | 9.5M | 8.5M | 1.3M | 97.0K |
| Pre-tax Income | 88.9M | -36.2M | -16.7M | 11.0M | -156.5M |
| Income Tax | 29.9M | 7.0M | -30.7M | -172.3M | 1.4M |
| Effective Tax Rate % | 33.6% | 0.0% | 0.0% | -1,563.0% | 0.0% |
| Net Income | 59.0M | -43.2M | 14.1M | 183.4M | -157.9M |
| Net Margin % | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% |
| Key Metrics | |||||
| EBITDA | 78.8M | -43.9M | -22.9M | 12.2M | -154.3M |
| EPS (Basic) | - | $-0.60 | $0.20 | $2.64 | $-2.30 |
| EPS (Diluted) | - | $-0.60 | $0.20 | $2.60 | $-2.30 |
| Basic Shares Outstanding | - | 71424159 | 70058952 | 69382275 | 68576810 |
| Diluted Shares Outstanding | - | 71424159 | 70058952 | 69382275 | 68576810 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Kiniksa Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 165.6M | 183.6M | 108.0M | 122.7M | 122.5M |
| Short-term Investments | 248.5M | 60.0M | 98.4M | 67.9M | 59.7M |
| Accounts Receivable | 15.6M | 41.7M | 21.3M | 12.7M | 4.0M |
| Inventory | 54.9M | 26.4M | 31.1M | 21.6M | 3.7M |
| Other Current Assets | 42.6M | 20.1M | 17.5M | 10.5M | 6.6M |
| Total Current Assets | 527.2M | 331.8M | 276.3M | 243.1M | 196.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 13.8M | 14.6M | 15.9M | 9.4M | 9.8M |
| Goodwill | 15.2M | 16.2M | 17.2M | 18.2M | 19.2M |
| Intangible Assets | 15.2M | 16.2M | 17.2M | 18.2M | 19.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 209.5M | 221.5M | 220.1M | 191.3M | 8.7M |
| Total Non-Current Assets | 236.5M | 248.8M | 250.0M | 216.6M | 36.4M |
| Total Assets | 763.6M | 580.6M | 526.3M | 459.7M | 232.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.0M | 2.0M | 8.2M | 7.9M | 1.9M |
| Short-term Debt | 3.0M | 2.0M | 2.3M | 3.3M | 3.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 22.1M | 16.1M | 8.2M | 5.8M | 1.5M |
| Total Current Liabilities | 139.2M | 100.6M | 63.7M | 47.1M | 44.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 6.5M | 7.9M | 10.0M | 2.6M | 2.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 18.5M | 1.8M | 1.9M | 1.8M | 270.0K |
| Total Non-Current Liabilities | 56.8M | 41.5M | 23.8M | 16.5M | 2.9M |
| Total Liabilities | 196.0M | 142.1M | 87.5M | 63.5M | 47.8M |
| Equity | |||||
| Common Stock | 21.0K | 20.0K | 20.0K | 19.0K | 18.0K |
| Retained Earnings | -462.1M | -521.1M | -478.0M | -492.0M | -675.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 567.6M | 438.4M | 438.8M | 396.1M | 185.0M |
| Key Metrics | |||||
| Total Debt | 9.5M | 9.9M | 12.3M | 5.9M | 6.0M |
| Working Capital | 388.0M | 231.2M | 212.6M | 196.0M | 151.6M |
Balance Sheet Composition
Kiniksa Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 59.0M | -43.2M | 14.1M | 183.4M | -157.9M |
| Depreciation & Amortization | 1.6M | 1.7M | 2.3M | 2.4M | 2.4M |
| Stock-Based Compensation | 37.0M | 30.7M | 27.1M | 25.1M | 25.2M |
| Working Capital Changes | 9.8M | -16.2M | -8.5M | -15.0M | -12.6M |
| Operating Cash Flow | 124.0M | -15.7M | 4.3M | 13.4M | -140.3M |
| Investing Activities | |||||
| Capital Expenditures | -1.6M | -252.0K | -130.0K | -14.0K | -415.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -386.9M | -202.0M | -204.9M | -135.9M | -157.2M |
| Investment Sales | 199.5M | 239.9M | 175.5M | 127.8M | 306.3M |
| Investing Cash Flow | -189.0M | 37.7M | -29.6M | -8.1M | 148.6M |
| Financing Activities | |||||
| Share Repurchases | -7.7M | -5.0M | -2.2M | -901.0K | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -7.7M | -5.0M | -2.2M | 2.5M | 0 |
| Free Cash Flow | 136.4M | 25.4M | 13.2M | 5.7M | -146.7M |
| Net Change in Cash | -72.7M | 16.9M | -27.4M | 7.9M | 8.3M |
Cash Flow Trend
Kiniksa Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
57.39
Forward P/E
29.15
Price to Book
5.78
Price to Sales
4.86
PEG Ratio
-0.22
Profitability Ratios
Profit Margin
8.71%
Operating Margin
9.78%
Return on Equity
11.73%
Return on Assets
7.18%
Financial Health
Current Ratio
3.79
Debt to Equity
1.67
Beta
0.06
Per Share Data
EPS (TTM)
$0.75
Book Value per Share
$7.44
Revenue per Share
$9.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| KNSA | 3.3B | 57.39 | 5.78 | 11.73% | 8.71% | 1.67 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Alkermes plc | 5.6B | 23.71 | 3.09 | 14.72% | 16.37% | 3.85 |
| Lantheus Holdings | 5.4B | 24.30 | 4.91 | 21.45% | 15.15% | 57.19 |
| Amneal | 4.2B | 63.23 | -57.42 | -101.02% | 2.39% | 45,095.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.






